Why Exact Sciences' Report Should 'Allay Fears Of A Market Slowdown'

investors.com/news/technology/exact-sciences-stock-exact-sciences-earnings-q3-2025/?src=A00220

stock surged Tuesday on a broad third-quarter beat that "should allay fears of a market slowdown," an analyst said.
The company is well known for Cologuard, a stool-based test that detects colon cancer. Screening revenue, which includes Cologuard tests, grew 22% to $666 million, easily…

This story appeared on investors.com, 2025-11-04 15:32:56.
The Entire Business World on a Single Page. Free to Use →